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Genetic factors exert an important role in determining Systemic Lupus Erythematosus (SLE) susceptibility, interplaying with
environmental factors. Several genetic studies in various SLE populations have identified numerous susceptibility loci. From a
clinical point of view, SLE is characterized by a great heterogeneity in terms of clinical and laboratory manifestations. As widely
demonstrated, specific laboratory features are associated with clinical disease subset, with different severity degree. Similarly, in the
last years, an association between specific phenotypes and genetic variants has been identified, allowing the possibility to elucidate
different mechanisms and pathways accountable for disease manifestations. However, except for Lupus Nephritis (LN), no studies
have been designed to identify the genetic variants associated with the development of different phenotypes. In this review, we will
report data currently known about this specific association.
1. Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease with multifactorial etiology, in which genetic and
environmental factors interplay determining disease suscep-
tibility [1].
Starting from 1970, several genetic studies in various
SLE populations have identified numerous susceptibility loci.
However, the genetic variability so far identified accounts for
less than half of the SLE heritability, withmodest overall effect
sizes (OR ∼ 1.5 to 1.2) (Figure 1) [2–7]. It is well established
that some specific genetic factors are not shared between all
SLE patients, excluding a role in the disease susceptibility and
suggesting an association with specific phenotypes (Table 1)
[6, 8]. However, this discrepancy could be related to multiple
mechanisms that can lead to SLE development.
As widely demonstrated, specific autoantibodies resulted
in being associated with different disease-related manifesta-
tions, identifying distinctive subset in terms of morbidity and
mortality and suggesting different underlying etiologies [9].
Similarly, in the last years, some studies have evaluated the
relationships between SLE risk genes and disease phenotypes,
in order to elucidate different mechanisms and pathways
accountable for disease manifestations. However, except for
Lupus Nephritis (LN), no studies have been specifically
designed to evaluate the genetic risk factors associated
with different manifestations. Therefore, these data could be
extrapolated from studies evaluating disease susceptibility,
which include a genotype-phenotype analysis.
2. Renal Involvement
Renal involvement could affect up to 60% of SLE patients,
as initial manifestation or during disease course. Despite
the improvement in terms of diagnostic accuracy and man-
agement, LN patients showed higher morbidity and mor-
tality compared with those without this manifestation [10].
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Figure 1: Schematic representation of genetic variants associated with SLE susceptibility identified from 1970.
Accordingly, the identification of markers able to identify
most severe disease and to predict the end-stage renal
disease (ESRD) development is a crucial topic. In particular,
during the last years, numerous attempts have been made
in order to identify serological and urinary biomarkers able
to discriminate the different severity degree and to monitor
response to treatment in LN patients, obtaining contrasting
results [11]. Moreover, the use of resistive index (RI) as a
severity marker in LN patients has been suggested in a recent
study published by Conti et al. The authors identified a
significant association between a pathologic RI (>0.7) and
class IV glomerulonephritis, widely identified as the most
severe [12].
In the context of biomarkers, genetic factors could have
an important role in SLE patients with renal involvement
in order to identify subject at risk to develop most severe
and rapidly progressive forms. Moving from the genetic
variants previously associated with disease susceptibility,
several studies have verified the association of the same alleles
with the presence of renal involvement.
The first genetic association described for SLE based on
the case-control methodology was with the human leucocyte
antigen (HLA) region at chromosome 6p21.3, encoding more
than 200 genes, many of them with a specific immunological
role. Seven HLA Class II alleles were demonstrated to be
significantly associated with SLE and LN [13]. The HLA-
DR2 and DR3 alleles resulted in being the most strongly
associated with SLE susceptibility in African, Asian, Euro-
pean, and North, Central, and South American populations,
even though HLA-DR3 tends to be more associated in
European-derived populations [8]. In particular, the asso-
ciation between the disease susceptibility and highly con-
served HLA-DRB1∗03:01 and HLA-DRB1∗15:01 haplotypes
has been well established in European populations [8]. The
punctual mechanism by which HLA-DR alleles determine
an increased risk to develop SLE is not completely defined.
The most reliable hypothesis suggests the influence of HLA-
DR on the selection and enrichment of autoreactive T cells
through the presentation of molecular mimics [14].
Moving from these premises, the association with renal
involvement has been investigated, showing the primary role
exerted by HLA-DR3 and DR-2 [15]. In particular, the results
obtained from the study conducted by Taylor and colleagues
in 2011 and by Bolin in 2013 showed the association between
HLA-DR3 and LN (OR = 1.37 and 𝑃 < 1×10−4, resp.) [16, 17].
Particularly, Bolin et al. found an association between HLA-
DR3 allele and proliferative nephritis (𝑃 < 0.001) [17].
Numerous evidences identified an association between
signal transducer and activator of transcription 4 (STAT4)
genetic variants and increased risk to develop SLE, suggesting
a role of these genetic variants in influencing disease pheno-
type.
In 2008, Taylor and colleagues analyzed a large SLE pop-
ulation, obtained from four sources (UCSF Lupus Genetics
Project; Autoimmune Biomarkers Collaborative Network;
Multiple Autoimmune Disease Genetics Consortium; Pitts-
burgh Lupus Registry) in order to evaluate the association
between SNP rs7574865 of STAT4 and the different SLE-
related manifestations. The phenotype case-only analysis
identified a significant association with the presence of severe
nephritis, defined as ESRD, or histopathologic evidence of
severe, progressive renal disease (OR = 1.50) [18]. Simultane-
ously, the study conducted by Kawasaki et al. in a Japanese
population confirmed the association between this STAT4
risk allele and renal involvement. In particular, the authors
identified the association with rs7574865 both in SLE patients
with nephritis (OR = 1.85) and in those without (OR = 1.55),
which was stronger in nephritis cases [19].
More recently, Bolin and colleagues evaluated a cohort
constituted by 567 Swedish Caucasian SLE patients and 512
healthy controls to elucidate the genetic components of LN
[17]. By performing a LN case/controls analysis, a signif-
icant association between the SNPs rs11889341, rs7574865,
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Table 1: Genetic variants associated with disease manifestations.
Disease
phenotypes Genetic variants associated with related SNPs
Skin
involvement
ITGAM rs1143679
FCGR2A rs1801274
IL-6 174G/C
VDR rs1168268
Serositis
TRAF3IP2 rs33980500, rs13190932, and
rs13196377
PTPN2 rs2542151
Kidney
involvement
HLADR2, HLADR3 rs2187668
STAT4 rs7574865, rs11889341, rs7568275, and
rs7582694
ITGAM rs1143683, rs1143679
IRF5 rs2004640, rs2079197, and rs10488631
IRF7 rs4963128
TNFS4 rs2205960
DNAse I Q222R
Neurologic
disorder
TREX1 rs922075, rs6776700, rs6442123,
rs2242150, and rs11797
Joint
involvement
ITGAM rs1143679
FGCR2A, FCGR3A
VDR rs3890733
Mir146a rs2910164
Hematological
features
IL-21 rs907715
STK17A haplotype TAGTC
Immunologic
disorders
Anti-dsDNA
HLADR2, HLADR3 rs2187668
STAT4 rs7582694, rs7574865
ITGAM rs1143679, rs9888739
IRF5 rsrs10488631
SSA/SSB
ITGAM rs1143679
IRF7 rs4963128
HCP5 rs3099855
HLADR3 rs2187668
RNP
ITGAM rs1143679
Sm
ITGAM rs7574865
aCL
HCP5 rs3099844
C3 reduction
Mir146a rs2910164
C4 reduction
TRAF3IP2 rs33980500
rs7568275, and rs7582694 of STAT4 gene and the devel-
opment of LN (𝑟2 = 0.98) was identified. In particular,
the rs7582694 allele resulted in being associated with the
presence of a proliferative nephritis (OR = 2.27) and with
the development of a severe renal insufficiency (defined as a
GRF< 30mL/min/1.73m2 at follow-up) (OR= 3.61) [17].This
associationwas not always confirmed. In the study conducted
by Li and colleagues in 2011 on a Northern Han Chinese SLE
population, the SNP rs7574865 of STAT4 did not show any
correlation with clinical manifestations [20].
Several hypothesis have been suggested to understand
the mechanisms by which STAT4 could contribute to LN
development. Interleukin-12 (IL-12), the main STAT4 acti-
vating cytokine, is able to induce the Th1 and Th17 dif-
ferentiation with consequent production of IFN-𝛾 and IL-
17. These specific pathways seem to be crucial for the LN
pathogenic mechanism: in particular, IL-17 could exert a
direct role, as demonstrated by the identification ofTh17 cells
in kidney tissue and by the association between high IL-17
levels and less favorable outcome [21].Moreover, SLE patients
carrying the STAT4 risk allele rs7574865 showed an increased
sensitivity to IFN-𝛼 signaling, as demonstrated by the over-
expression of IFN-𝛼 regulated gene. Among these, TNFSF13B
codifies the B lymphocyte stimulator (BLyS), which is able to
promote B cell differentiation and autoantibody production
[22].
The influence of ITGAM genetic variants on SLE suscep-
tibility has been demonstrated in populations with different
ethnicity: in particular, convincing data derived from Euro-
pean ancestry, but also from Hispanic, African-Americans,
Mexicans, and Colombians cohorts [23]. Moving from these
results, the association with specific clinical manifestations
has been investigated. In 2009, Yang and colleagues identified
a significant association between renal involvement and the
ITGAM risk alleles rs1143683 and rs1143679 (OR = 3.35, OR
= 2.05, resp.) in a Hong Kong SLE cohort [24]. Moreover,
this association was confirmed in an analysis conducted on
Finnish and Swedish population of patients affected by SLE.
The authors observed increased risk in SLE patients with
renal involvement, with an OR = 2.49 for the rs1143679 SNP
[25].
The study conducted by Kim-Howard and colleagues
in 2010 on a very large population, constituted by 2366
SLE patients and 2931 unaffected controls with European
ancestry, confirmed the link between the genetic variant
rs1143679 of ITGAM and renal disorders as defined by the
American College of Rheumatology (ACR) criteria (OR =
1.39) [26]. To better assess the magnitude of this association,
a comparison between patients with the specific ACR-criteria
renal manifestations and healthy controls was performed.
This statistical approach allowed the identification of a strong
effect concerning the association with renal criteria (OR =
2.15) [26].
More recently, in 2011 Sanchez et al. confirmed this asso-
ciation (OR = 1.25) by evaluating a population constituted
by 4001 European-derived, 1547 Hispanic, 1590 African-
American, and 1191 Asian patients. This association seems
to be driven prevalently by the European-derived cohort, as
demonstrated by a higher OR in this specific subset (OR =
1.39) and by the lack of a significant association with African-
American or Asian individuals [27].
ITGAM encodes the CD11b chain of the Mac-1 (alphaM-
beta2; CD11b/CD18; complement receptor-3) integrin, a sur-
face receptor protein implicated in the interaction of mono-
cytes, macrophages, and granulocytes. The genetic variants
of this molecule, resulting in amino acid substitution in
the extracellular portion, could determine a dysfunctional
integrin, not able to mediate cell adhesion to integrin ligands
and phagocytosis. Moreover, this defective integrin does not
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seem to be able to restrict the production of inflammatory
cytokines in macrophages [28].
Under physiological conditions, ITGAM is expressed
by endothelial cells of glomerular and peritubular capil-
laries of Bowman’s capsule. It has been suggested that an
increased expression of a defective molecule, due to the
presence of a genetic variant, could be associated with a
loss of clearance of glomerular deposits, with inflammatory
process development [26]. Similarly, defective handling of
immune complexes could be the mechanism explaining the
association between genetic variants of FCGR3A and kidney
involvement in SLE patients. A meta-analysis conducted by
Karassa and colleagues in 2003 evaluated the study examining
the association of the FCGR3A V/F158 polymorphism and
LN, published until August 2002 [29]. Data deriving from
the analysis on 16 studies demonstrated a significant over-
representation of the low-binding F158 allele in patients with
renal disease compared with those without (𝑃 = 0.003).
Moreover, the presence of this allele seems to confer a 1.2-
fold greater risk for renal disease development, irrespective
of the ethnicity [29]. More recently, the PROFILE cohort,
constituted by 1008 SLE patients, with renal involvement in
43.4% of the cases (438 patients), was evaluated in order to
identify the association with FCGR3A polymorphism. The
authors identified an overrepresentation of FCGR3A∗GG in
SLE patient developing ESRD (21.9%) compared with those
who did not develop it (7.5%) (𝑃 = 0.0175) [30]. Interestingly,
the evaluation of FCGR3A variants demonstrated different
genetic association for the global lupus phenotype and for the
renal involvement (FCGR3A∗T and FCGR3A∗GG, resp.).
This observation confirms the hypothesis of different genetic
background for susceptibility and disease phenotype, leading
to different pathogenic mechanisms associated with the
corresponding molecule [30].
FCGR plays a pivotal role in removing antigen-antibody
complexes at the tissue and organ level. Allelic variants could
alter this function, causing an inflammatory response with
damage development. In particular, as widely demonstrated,
a homozygosity condition for this FCGR3A SNP could
lead to impaired handling of immune complexes, causing a
proinflammatory status [29, 30].This could justify the impact
of genetic variants of FCGR3A in the determination of a
specific phenotype, such as renal involvement.
In the last 20 years, the role of Interferon (IFN) signature
in the SLE pathogenesis has been recognized, as demon-
strated by the dysregulation in the expression of genes in the
IFN pathway inmore than half of SLE patients [31]. IFN path-
way is involved in several pathologic mechanisms, involving
Th1 and B cells activation and survival. Moreover, IFN acts
as a bridge between innate and adaptive immune systems.
Interferon Regulatory Factors (IRF) ensure the regulation of
this complex pathway, by acting on signaling and immune
cell development [31]. Genetic variants of IRF5, IRF7, and
IRF8 genes have been associated with SLE susceptibility (OR
= 1.88, OR = 0.78, and OR = 1.17, resp.) since they associated
with increased levels of protein expression [32]. Starting from
these evidences, the association with renal involvement in
SLE patients has been investigated. The study conducted
on 190 LN patients and 182 healthy Chinese blood donors
demonstrated a significantly higher frequency of the T allele
of IRF5 rs2004640 SNP in LN patients (OR = 1.60) [33].
The abovementioned study conducted by Bolin and
colleagues in 2013 identified a strong association between LN
and two nearly perfectly linked SNPs in IRF5 (rs2070197 and
rs10488631, 𝑟2 1.0). In particular, the risk allele C of rs10488631
was associated with proliferative nephritis (OR = 2.61) and
severe renal insufficiency (OR = 3.03) [17]. More recently, an
association between IRF7 rs4963128 and LN (OR = 2.69) has
been identified in the study conducted by Li and colleagues
in 2011 in a Northern Han Chinese population [34].
In 2011, for the first time, Sanchez and colleagues sug-
gested a new interesting genetic factor related to renal dis-
orders in SLE patients by identifying a significant association
with rs2205960 TNFSF4 risk allele (OR = 1.14) [27]. TNFSF4,
also called OX40L, is a member of the TNF superfamily,
expressed prevalently on antigen-presenting cells; activated
T cells express the receptor of this molecule (TNFSFR4 or
OX40) [35]. The expression of TNFSF4 at the epithelial level
of the glomerular capillary has been demonstrated in LN
patients [36]. More recently, Zhou and colleagues demon-
strated a modification of cytokine production in PBMC in
LN patients after treatment with anti-CD134 monoclonal
antibody [37]. Finally, significantly higher TNFSF4 serum
levels have been demonstrated in SLE patients with renal
involvement, compared with patients without nephritis, sug-
gesting the role of this molecule as a marker. Moreover, the
increased expression on CD4 positive T cells seems to be
associated with LN and disease activity [38]. Taken together,
these evidences could justify the link between a genetic
variant in the TNFSF4 gene and renal involvement.
Several other genetic variants have been associated with
kidney manifestations in SLE patients. Panneer and col-
leagues suggested the role of polymorphism in the gene
codifying the DNAse I, an endonuclease involved in the
cleavage and clearance of chromatin during apoptotic pro-
cesses [39]. The reduction of the DNAse I function, related
to the genetic modification, could alter this cleavage and
the clearance of immune-complexes and NETs, resulting in
the persistence of apoptotic debris [40]. By evaluating 300
South Indian Tamil SLE patients, the authors identified a
significantly higher frequency of heterozygous genotype of
Q222Rpolymorphism in patientswith nephritis than in those
without (67% versus 53%, OR = 1.93) [39]. Some interesting
data concerning the association between LN development
and polymorphism on the gene codifying C1q have been
recently published [41, 42]. However, due to the small cohorts
evaluated in these studies, their results should be confirmed
in large populations.
3. Neuropsychiatric Manifestations
Neuropsychiatric SLE is a major disease manifestation,
characterized by a wide heterogeneity in terms of clinical
features, degrees of morbidity, and severity between patients
[43]. A percentage of SLE patients ranging from 14 to 75%
may refer to neurological symptoms: this wide variability is
probably related to the great heterogeneity of this disease
manifestation. Despite the relevance of this involvement,
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studies focusing on genetic variants specifically associated
with NPSLE have been rarely conducted. Nonetheless, Koga
and colleagues in 2011 evaluated 282 Japanese SLE patients
and 222 healthy controls in order to assess the cumula-
tive number of risk alleles associated with SNPs of HLA-
DRB1, IRF5, STAT4, BLK, TNFAIP3, TNIP1, FCGR2B, and
TNFSF13 genes. SLE patients registered a significantly higher
number of risk alleles compared with controls (8.07 ± 1.60
versus 7.02 ± 1.64, 𝑃 = 1.63 × 10−12). Interestingly, when
considering SLE patients carrying more than 10 risk alleles,
the proportion of patients with neurological involvement was
significantly higher compared with subjects with a number
of risk alleles lower than 10 (OR = 2.30). This result could
suggest that a higher number of risk alleles could determine
most severe disease manifestations [44].
Genetic variants in TREX1 gene, codifying a threeprime
repair exonuclease 1 (also known as DNAse III), have been
considered a good candidate for NPSLE. de Vries and
colleagues scanned genomic DNA of 60 NPSLE patients for
exonic TREX1 mutations using direct sequencing. This study
identified a novel heterozygous p.Arg128His mutation in one
NPSLE patient, admitted to the hospital because of lethargy
and progressive migraine-like headache [45]. The authors
suggested that the p.Arg128His mutation is responsible for
neurological manifestations at the light of the absence of
this mutation in 400 control chromosomes and in 1712
healthy individuals, previously screened by Lee-Kirsch et al.
[46]. More recently, this association has been confirmed in
the study conducted by Namjou and colleagues in 2011. By
evaluating the European population enrolled in the analysis,
the authors identified a significant association between the
presence of neurological manifestations (as defined by ACR
criteria), especially seizure, and specific variants in TREX1
gene. In particular, the rs922075 (OR= 1.644); rs6776700 (OR
= 1.689); rs6442123 (OR = 1.747); rs2242150 (OR = 1.638);
rs11797 (OR = 1.714) SNPs resulted in being significantly
associated [47].
4. Joint Involvement
Joint involvement is a frequent manifestation in patients with
SLE and could affect up to 90% of patients. A wide hetero-
geneity, varying from arthralgia to erosive arthritis similar
to rheumatoid arthritis, characterizes this manifestation [48].
Nevertheless, the number of reports is relatively scarce.
Concerning the identification of specific genetic variants, few
studies have evaluated the associationwith joint involvement.
ITGAM gene risk variants have been associated with
arthritis in SLE patients. The study conducted by Warchoł
et al. in 2011 in a Polish SLE population demonstrated
an association between the rs1143679 genetic variant and
occurrence of arthritis (OR = 3.486) [49].
A strong association with arthritis and Vitamin D Recep-
tor (VDR) polymorphism was identified in the study con-
ducted by de Azeveˆdo Silva and colleagues in 2013 [50].
Through the Vitamin D Receptor (VDR), Vitamin D exerts
an immune-modulatory effect. In particular, it intervenes
in downregulation of Th1 immune response, modulation of
dendritic cells differentiation, depressing activated B cell pro-
liferation, upregulation of regulatory T cells, and preserving
immune response [50]. A number of evidences showed that
patients with SLE often present reduced levels of Vitamin
D suggesting an involvement of this molecule in disease
pathogenesis [51]. There is still a debate concerning the
precise role of VDR in SLE [52]. The study conducted by
de Azeveˆdo Silva in 2013 did not identify any association
between VDR polymorphism and SLE susceptibility. Con-
versely, the T/T genotype (rs3890733) resulted in being sig-
nificantly associated with the presence of joint involvement
(OR = 17.05). The authors underlined that this association
should be interpreted with caution because the frequencies
observed for this VDR polymorphism were not in Hardy-
Weinberg equilibrium [50].
Other associations between genetic variants and joint
involvement have been suggested: some data identified an
association with C4 and ACP5 genetic variants, but no
replication studies are available [53, 54]. Moreover, Cic-
cacci and colleagues identified an association between joint
involvement and rs2910164 of mir146a gene (OR = 1.93) [55].
The association between arthritis and the FCGR2A and
FCGR3A low copy number genotype has been identified in
a cohort of Taiwan SLE patients [56, 57]. In particular, in the
most recent study, the FCGR3A low copy number genotype
was significantly enriched in SLE patients with arthritis (𝑃 =
0.001; OR = 1.56) [57].
Finally, the study conducted by Fonseca et al. in 2013 iden-
tified an association between arthritis and the SNP rs15866
of STK17A gene (OR = 2.92), encoding serine/threonine-
protein kinase 17A [58]. The mechanism explaining this
association is not clarified and replication studies are needed
to confirm these results.
5. Skin Manifestations
Skin involvement represents a frequent manifestation in SLE
patients (up to 75%), characterized by a great heterogeneity,
including acute and chronic phenotypes. Some genetic vari-
ants have been associated with different skin manifestations
in SLE cohorts.
ITGAM genetic polymorphisms are to date the most
frequently associated variants with skin involvement. In 2010,
Kim-Howard et al. have identified an association between
malar rash and the polymorphism rs1143679 of ITGAM (OR
= 1.27) [26]. Moreover, the presence of discoid rash resulted
in being associated with ITGAM rs1143679 (OR = 1.20) in the
study conducted by Sanchez et al. in 2011 [27].
Ja¨rvinen and colleagues conducted an analysis specifically
designed to address the role of ITGAM genetic variants in
a cohort of Finnish and Swedish patients with discoid LE,
without signs of systemic disease. The analysis demonstrated
a strong association between the allele rs1143679 and DLE
(OR = 3.2). The authors identified a significant association
also in SLE patients with discoid rash (OR = 3.76). Moreover,
other variants in ITGAM resulted in being associated with
these manifestations, but the authors hypothesized that the
strong linkage disequilibrium with rs1143679 could explain
this result [25].
6 Journal of Immunology Research
The link between ITGAM and photosensitivity, fre-
quently identified in patients with discoid LE, could explain
this association. Ultraviolet- (UV-) B irradiation determines
the activation of several proinflammatory events at the skin
level, involving prevalently macrophages ITGAM-expressing
and dendritic cells. Genetic-determined modification in the
function of ITGAM could modify the processes regulating
the dendritic cell differentiation, inducing inflammatory
reactions in discoid LE patients [25]. On the other hand,
the absence of CD11b seems to enhance the differentiation of
naive T cells to IL-17 producing Th17 cells, determining the
increase of IL-17 serum levels, identified in discoid LE and
SLE patients with skin involvement [59].
Moreover, genetic variants of FCGR2A seem to be asso-
ciated with skin manifestations. In particular, Sanchez and
colleagues identified an association between malar rash and
FCGR2A rs1801274 (OR = 1.11) [27].
The abovementioned study conducted by de Azeveˆdo
Silva et al. in 2013 identified an association between the SNP
rs11168268 of VDR and cutaneous alterations in a cohort of
Brazilian SLE patients [50]. Photosensitivity, one of the most
common cutaneous alterations described in SLE patients
derives from the exposure to UV light, causing a macular
or erythematous rash. After UV exposure, keratinocytes
begin apoptotic process due to DNA damage with release
of nuclear material. A defective clearance of apoptotic body
could trigger an immune response. Vitamin D has proved
to be able to reduce the UV-induced DNA damage and
suppress cutaneous immunity, playing an important role in
the maintenance of cell integrity after UV light exposure
[60]. The presence of genetic variants in VDR, expressed in
the skin epithelial cells, could modify this Vitamin D ability,
promoting cutaneous alterations in SLE patients [61].
A recent meta-analysis identified a significant association
between the IL-6-174 G/C polymorphism and discoid skin
lesions by the evaluation of 15 studies (OR = 2.271). These
results support the role of IL-6 in the pathogenesis discoid
skin lesions [62].
6. Serositis
Few data are available in the literature about the genetic
risk for the serositis development. The study published by
Perricone et al. in 2013 identified an interesting correlation
between the TRAF3IP2 SNPs and the development of peri-
carditis. The authors identified a significant association with
the three TRAF3IP2 SNPs evaluated (rs33980500: OR = 2.59;
rs13190932: OR = 2.38; rs13196377: OR = 2.44). Moreover,
the authors analyzed the contribution of SLE antibody to the
development of this specific manifestation, showing a signif-
icant association between the risk to develop pericarditis and
anti-La/SSB positivity (OR = 2.65). A binary logistic regres-
sion analysis demonstrated that both TRAF3IP2 rs33980500
and anti-La/SSB could be independently associated with the
development of pericarditis (𝑃 = 0.006 and 𝑃 = 0.032, resp.)
[63]. In this study, for the first time, the role of TRAF3IP2
genetic variants on SLE susceptibility has been ascertained.
Interestingly, TRAF3IP2 polymorphism resulted also in being
associated with a specific disease manifestation. TRAF3IP2
codifies the molecule Act1, which from one side is involved
in the IL-17 pathways, but it is also a negative regulator of the
CD40-mediated signaling pathway [64, 65].
The study conducted by Ciccacci and colleagues in 2014
identified a new association between the occurrence of
pericarditis and the genetic variant rs2542151 of PTPN2 gene
(OR = 2.49) [55]. PTPN2 codifies the enzyme tyrosine-
protein phosphatase nonreceptor type 2, a member of the
protein tyrosine kinases (PTP) superfamily. PTPN2 genetic
variants have been previously associatedwith susceptibility to
both Crohn’s disease and ulcerative colitis and with an earlier
onset of type 1 diabetes [66, 67]. The abovementioned study
by Ciccacci and colleagues analyzed for the first time the role
of PTPN2 genetic variants in the SLE susceptibility, with-
out identifying significant differences between patients and
healthy controls. Conversely, the SNP rs2542151 of PTPN2
resulted in being associated with serositis, and specifically
with pericarditis [55].The relevance of this association should
be clarified by larger studies.
7. Hematological Manifestations
Similarly to the other SLE-related manifestations, few studies
focusing on the association between genetic variants and
hematological features have been conducted to date. The
extrapolation from genotype-phenotype studies identified
some associations. Among these, Sanchez and colleagues in
2011 identified an association between hematological features
and IL-21 rs907715 (OR = 1.13). When the different ACR
hematological criteria were analyzed, an association with leu-
copeniawas confirmed (OR= 1.14). IL-21, primarily produced
by activated CD4+ T cells, is involved in differentiation and
functional activity of T and B cells [68–70]. This evidence
could justify this association, by hypothesizing that a genetic
variant of IL-21 could be related to a modification of this
activity on B and T cells, influencing disease phenotype.
More recently, Fonseca et al. in 2013 described a signif-
icant association between hematological features and hap-
lotype TAGTC of STK17A gene (OR = 0.03). The patients
stratification according to ethnicity and gender suggested a
protective role of this haplotype on hematological manifesta-
tions development (OR 0.37) [58]. Similarly to the association
with arthritis, the mechanism explaining this association is
not identified and other replication studies are needed to
confirm these results.
8. Immunological Abnormalities
The production of a wide range of autoantibodies, result-
ing from polyclonal B cells activation, impaired apoptotic
pathways, or idiotypic network dysregulation, characterizes
SLE [1, 71]. Among these, the anti-double-stranded DNA
antibodies (anti-dsDNA) are considered the most specific
marker for SLE, due to their high frequency (ranging from
70% to 98%) and sensitivity and specificity (57.3% and 97.4%,
resp.) [72, 73].
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Several evidences suggested a role of genetic factors in
autoantibodies determination [74]. The same genetic vari-
ants, previously described as associated with renal involve-
ment, have been investigated in order to identify a link
with anti-dsDNA production. Since 1998, Podrebarac and
colleagues described the association between anti-dsDNA
production and the presence of HLA-DRB1∗1501 (DR2)
allele [75]. More recently, the association between HLA-
DR2 and DR3 with the presence of anti-dsDNA has been
confirmed by several analysis [16, 76].
Starting from 2008, the association between the STAT4-
risk allele of the SNP rs7582694 and positivity for anti-
dsDNA has been identified by different studies [16, 18, 77].
Finally, ITGAM polymorphism has been also associated
with the presence of anti-dsDNA. In particular, the study
conducted by Kim-Howard and colleagues in 2010 identified
an associationwith rs1143679 (OR 1.65) in a case-only analysis
performed by comparing SLE patients positive and negative
for anti-dsDNA [26].
Four years ago, Chung and colleagues conducted the
first genome wide study focused to identify genetic factors
associated with anti-dsDNA autoantibody production, by
analyzing 1278 SLE cases and 3334 healthy controls of Euro-
pean descent [78]. Genetic variants STAT4 (rs7574865), IRF5
(rs10488631), ITGAM (rs9888739), and MHC (HLA-DR3,
rs2187668) resulted in being strongly associated with anti-
dsDNA positivity (OR = 1.77, OR = 1.92, OR = 1.80, and OR
= 2.23, resp.). Moreover, the authors assessed the relationship
between the anti-dsDNA autoantibody production and the
cumulative genetic risk, calculated by counting the total
number of risk alleles identified in a single subject. The
mean SLE genetic risk was higher in SLE patients positive
for anti-dsDNA (15.5 ± 3.1) compared with anti-dsDNA
negative patients (14.5 ± 3.0) and healthy controls (13.1 ±
2.8), even though this difference was not significant [78].
The results of this study suggest that some genetic variants
are more strongly associated with anti-dsDNA autoantibody
production than with SLE susceptibility, and they could be
described as “autoantibody propensity genes” [78].
Even though the majority of the studies have focused on
the anti-dsDNA antibodies, some evidences demonstrated an
association between genetic variants and production of other
autoantibodies in patients affected by SLE.
Ja¨rvinen and colleagues in 2010 identified an association
between the polymorphism rs1143679 in ITGAM gene and
the presence of Ro/SSA autoantibodies in the Finnish (OR =
2.65) and Swedish (OR 1.62) populations [25]. The involve-
ment of both Ro-autoantibodies and the ITGAM protein
product in the same biological pathways of apoptosis and
phagocytosis could explain this association, which remains
mostly unknown [25].
The study conducted by Li and colleagues in 2011 sug-
gested a new association between IRF7 rs4963128 polymor-
phism and anti-SSA/SSB (OR = 0.61) [20]. Moreover, the
study conducted by Ciccacci and colleagues in 2014 identified
for the first time an association between anti-Ro/SSA and
HCP5 rs3099855 polymorphism (OR = 2.28) [55]. This SNP
has been previously associated not only with Steven Johnson
syndrome and toxic epidermal necrolysis susceptibility, but
also with primary sclerosing cholangitis, another autoim-
mune condition [79, 80]. More interestingly, as demonstrated
by a genome-wide association study, the same polymorphism
resulted in being associated with cardiac manifestations
of SLE, a clinical condition frequently associated with the
presence of anti-Ro/SSA antibodies [81]. These data suggest
a pathological link between anti-Ro/SSA antibodies and this
HCP5 polymorphism, requiring further studies to clarify
the specific underlying mechanisms. Moreover, both anti-
Ro/SSA and anti-La/SSB autoantibodies resulted in being sig-
nificantly associatedwithHLA-DRB1∗03:01 (OR= 1.60,OR=
2.57, resp.), as demonstrated by the largest SLE subphenotype
genetic association study conducted so far [82].
A recent study published by Niewold et al. in 2012
evaluated the association between IFR5 haplotype and dif-
ferent SLE-related manifestations. Interestingly, the authors
identified a strong and strikingly distinct association between
different autoantibodies and different IRF5 haplotypes. In
particular, TACA haplotype was associated with anti-dsDNA
and anti-Ro/SSA (OR= 1.5, OR = 1.51, resp.), TATAhaplotype
with anti-dsDNA (OR = 1.68), and TCTA haplotype with
anti-La/SSB (OR = 3.51) [83]. These results suggest the
possible role of IRF5 genotype to predispose the antibodies
formation: IRF5 haplotypes could influence susceptibility
to form particular antibodies. Immune complexes contain-
ing these antibodies are internalized into cells, and the
nucleic acid component could trigger endosomal TLR7 and
TLR9. The presence of IRF5 SLE-risk variants could increase
IFN-𝛼 production in the setting of different antibodies,
resulting in high serum IFN-𝛼 and subsequent SLE risk
[83].
The studies published until now have suggested other
associations between specific autoantibodies and genetic
variants, among which are the associations between anti-
RNP and rs1143679 of ITGAM (OR = 1.89), anti-RNP and
rs56203834 of TREX1 in European populations (OR = 5.2),
anti-Sm and rs7574865 of ITGAM (OR = 0.65), and anti-
cardiolipin and rs3099844 of HCP5 (OR = 0.34) [20, 26, 47,
55]. However, all these associations should be confirmed in
larger populations and the mechanisms explaining must be
identified.
The reduction of C3 and/or C4 serum levels represents a
frequent manifestation in patients affected by SLE and could
correlate with disease activity [84]. A strong association was
well established between homozygous hereditary deficiency
of each of the early proteins of the classical pathway of
complement activation and SLE development.The deficiency
of the C1 complex proteins and of total C4 is recognized as
the most prevalent and most severe disease. Indeed, more
than 75% of all individuals with deficiency of one of these
proteins develop SLE [84]. Conversely, the deficiency of C2
protein seems to be associated with lower prevalence of
disease (10%), while C3 deficiency is rarely associated with
SLE development, probably due to the rarity of homozygous
C3 deficiency [84]. Even though the association between
complement proteins deficiency and SLE development has
been largely clarified, very few data are available concerning
genetic variants associated with C3 and C4 levels reduction,
extrapolated by studies not focusing on this specific aspect.
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A correlation between C4 reduction and the SNP rs33980500
of TRAF3IP2 has been identified in the study conducted by
Perricone et al. (OR = 1.96) [63]. Conversely, the reduction
of C3 serum level was associated with the genetic variant
mir146a rs2910164 (OR = 1.91) [55].
9. Age at Disease Diagnosis
The evaluation of the studies published so far identified
interesting data concerning the influence of STAT4 genetic
variants on age at diagnosis. The SNP rs7574865 of STAT4
resulted in being associated with age at diagnosis lower
than 30 years (OR = 1.22) [16, 18]. The frequency of the
same genetic variant resulted in being slightly higher in SLE
Japanese patients with an age of onset lower than 20 years
as compared with patients with age ≥ 20 years, although this
difference was not statistically significant [19].
Moreover, rs2233945 of PSORS1C1 resulted in being
associated with age at diagnosis. Ciccacci and colleagues
observed that patients carrying the variant allele present a
lower mean age at disease onset compared with those not
carrying the variant (28.6 ± 11.57 years versus 32.2 ± 11.46
years, 𝑃 = 0.042) [55].
10. Chronic Damage
The increase of survival of SLE patients determined the
accrual of cumulative organ damage: adverse events of
treatment, disease activity, and comorbidities seem to be the
major risk factors. The prevention of damage development
is a critical issue in the management of SLE patients, as
underlined by the recent treat-to-target recommendations
[85]. Consequently, the identification of specific biomarkers,
able to identify SLE patients with a major risk to develop
chronic damage, is an attractive topic. Among the different
biomarkers, genetic variants could play a role. The study
conducted by Carvalho and colleagues in 2015 suggested a
role of VDR polymorphism [86]. The evaluation of 170 Por-
tuguese SLE patients and 192 healthy controls demonstrated
an association between different genetic variants and accrual
damage. In particular, the frequency of VDR genotypes TaqI
TT (rs731236) and Fok I CT (rs2228570) was higher in SLE
patients with damage, evaluated by using the SLICC Damage
Index (SDI) [86, 87].
The development of osteoporosis with fractures is con-
sidered chronic damage in SLE patients and is inserted in
the SDI [87]. Bonfa´ and colleagues performed a case-control
study by evaluating 211 premenopausal SLE patients and
154 healthy women, in order to evaluate the association
between the RANKL, OPG, and RANK gene polymorphisms
and bone parameters. A significantly lower frequency of the
RANKL 290 G allele (AG/GG) was identified in the patients
with vertebral fractures compared with those without (𝑃 =
0.011). In the logistic regression analysis, in addition to
the age, only RANKL 290A>G remained as an independent
risk factor for vertebral fractures in SLE patients [88]. The
authors hypothesized that the protection against vertebral
fractures that is associated with the AG/GG genotype could
be a consequence of decreased osteoclast activation due to
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Figure 2: Disease manifestations associated with ITGAM genetic
variants.
RANKL dysfunction or to a local reduction of this molecule
in the bone [88].
11. Conclusion
As widely demonstrated, genetic factors play a pivotal role
in SLE pathogenesis. Moreover, in the last years several evi-
dences suggested the role of genetic factors not only in disease
susceptibility, but also in the development of specific disease
phenotype. Several data are available to date concerning
genetic variants involved in renal involvement, while fewer
studies have been focused on SLE clinical and immunological
manifestations. Interestingly, some genetic variants seem
to be involved in the determination of different disease-
related manifestations, suggesting a common pathogenetic
mechanism, able to identify specific subset of patients. An
example of this concept is represented by ITGAM genetic
variants that resulted in being simultaneously associated
with different disease manifestations (Figure 2). The recent
progress leading to the discovery of novel methods to per-
form genetic studies will definitely allow clearly defining the
associations between genes variability and SLE susceptibility
and phenotype. Possibly, risk algorithms will be developed
permitting a more personalized management of the disease.
However, small populations and lack of all clinical data
characterize the studies evaluating the association between
genetic and different disease phenotypes, not allowing a suf-
ficient statistical power. Further studies specifically designed
to evaluate this issue are needed to clarify the strongest
associations.
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